Changes To Generic Drug Bioequivalence Requirements Could Mean Higher Study Costs
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Pharmaceutical Science and Clinical Pharmacology Advisory Committee agrees with the Office of Generic Drugs that bioequivalence standards should be tighter for generic versions of "critical dose" or "narrow therapeutic index" drugs.